Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inetetamab + sirolimus
- Development stage
- Preclinical
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **inetetamab**, a monoclonal antibody targeting HER2 with enhanced antibody-dependent cellular cytotoxicity (ADCC), and **sirolimus**, an mTOR inhibitor. The combination is used for treating HER2-positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway, particularly those who have progressed after trastuzumab treatment. It is often combined with chemotherapy.
- Other names
- inetetamab + sirolimus
02
Targets
Mechanistic target of rapamycin complex 1ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on inetetamab + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inetetamab + sirolimus.